Celularity, Inc. (CELU)
|Net Income (ttm)||-290.80M|
|Trading Day||July 23|
|Day's Range||9.26 - 9.96|
|52-Week Range||7.73 - 13.40|
The SPAC closed its merger with clinical-stage biotech Celularity.
GXGX's merger announcement is causing the stock to soar this afternoon. The SPAC is merging with biotech play Celularity.
Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital Market under the ticker symbol “CELU” on July 19, 2021
NEW YORK, May 14, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, announced today that its stockholders have voted to approve an a...
NEW YORK, May 10, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, today reaffirmed its intention to support the proposal to amend ...
GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination
NEW YORK, April 16, 2021 /PRNewswire/ -- On April 14, 2021, GX Acquisition Corp. ("GX") (NASDAQ: "GXGX"), provided information regarding a proposal to amend GX's amended and restated certificate of inco...
GX Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2018 and is based in New York, New York.
|Stock Exchange |
|Ticker Symbol |
In 2020, Celularity's revenue was $14.28 million, a decrease of -32.48% compared to the previous year's $21.15 million. Losses were -$208.23 million, -1.72% less than in 2019.